BCL2 and breast carcinoma: Bcl-2 inhibition by ABT-199 treatment showed synergistic viability decreases when used in combination with doxorubicin in breast cancer, supporting the notion that Bcl-2 inhibition can sensitize cancer cells to chemotherapy [146].